<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456351</url>
  </required_header>
  <id_info>
    <org_study_id>NHL 2-2003</org_study_id>
    <nct_id>NCT01456351</nct_id>
  </id_info>
  <brief_title>Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab</brief_title>
  <official_title>Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study addresses the question if a therapy with bendamustine plus rituximab is comparable
      (non inferior) with the well-tried combination of fludarabine plus rituximab with regard to
      event free survival (EFS) in recurrent low malignant Non-Hodgkin and mantle cell lymphomas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Observation till event or death, minimum 1 year</time_frame>
    <description>From date of randomization until the date of first documented progression, date of detection of a secondary malignancy or date of death from any cause, whichever came first. Minimum 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission Rates</measure>
    <time_frame>Observation till event or death, minimum 1 year</time_frame>
    <description>From date of randomization until the date of first documented progression, date of detection of a secondary malignancy or date of death from any cause, whichever came first. Minimum 1 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bendamustine plus Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine plus Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine plus Rituximab</intervention_name>
    <description>Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles</description>
    <arm_group_label>Bendamustine plus Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w</intervention_name>
    <description>Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles</description>
    <arm_group_label>Fludarabine plus Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological verified CD20-positive B-Cell-Lymphomas of the following
             entities:

          -  Follicular lymphoma grade 1 and 2

          -  Immunocytoma and lymphoplasmocytic lymphoma

          -  Marginal zone lymphoma, nodal and generalised

          -  Mantle cell lymphoma

          -  lymphocytic lymphoma (CLL without leucaemic characteristics)

          -  non-specified/classified lymphomas of low malignancy

          -  Recurrent disease (remission duration minimum 3 months), independent of type or
             quantity of prior therapies, except of Rituximab containing regimens, or if remission
             duration is &gt; 1 year after Rituximab containing regimen, or refractory to prior
             therapy (progression under therapy or during 3 months after completion), except
             refractory disease to purin analogs or Bendamustine

          -  Need for therapy, except mantle cell lymphomas

          -  Stadium II (bulky disease, 7.5 cm), II or IV

          -  Written informed consent

          -  Performance status WHO 0-2

          -  Histology not older than 6 months

        Exclusion Criteria:

          -  Patients not establishing all above mentioned prerequisites

          -  Option of a primary, potentially curative radiation therapy

          -  Patients refractory to Rituximab containing regimens

          -  Comorbidities excluding a study conform therapy:

        heart attack during the last 6 months severe, medicinal not adjustable hypertonia severe
        functional defects of the heart (NYHA III or IV) lung (WHO grade III or IV) liver or kidney
        (creatinine &gt; 2 mg/dl, GOT + GPT or bilirubin 3 x ULN, except caused by lymphoma

          -  Active auto immunohemolytic anemia (AIHA)

          -  HIV positive patients

          -  Active hepatitis infection

          -  Severe psychiatric diseases

          -  No compliance or non-compliance to be expected

          -  Pregnant or breast feeding women

          -  Anamnestic malignancies or secondary malignancies, not proven

          -  Cured/curable by surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>StiL Head Office; Justus-Liebig-University</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.stil-info.de</url>
    <description>Homepage of the Study group of indolent lymphomas (StiL)</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Jurgen Barth</investigator_full_name>
    <investigator_title>Professor Mathias Rummel</investigator_title>
  </responsible_party>
  <keyword>Event free survival</keyword>
  <keyword>Remission rates</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Efficiency costs</keyword>
  <keyword>Recurrent low grade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

